Goldman Sachs
SNTI icon

Goldman Sachs’s Senti Biosciences Holdings SNTI Stock Holding History

Goldman Sachs’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,250
Closed -$814K – 6691
2022
Q1 		$814K Hold
8,250
– – ﹤0.01% 4991
2021
Q4 		$813K Hold
8,250
– – ﹤0.01% 5024
2021
Q3 		$820K Hold
8,250
– – ﹤0.01% 4898
2021
Q2 		$820K Buy
+8,250
New +$823K ﹤0.01% 4902

Other funds holding SNTI

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
IC
Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
KC
Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

Goldman Sachs's SNTI Position: Q2 2022 in Review

Goldman Sachs sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 8,250 shares — an estimated $814K sold.

Goldman Sachs first reported a position in SNTI in Q2 2021 and held it in 4 quarters. The position peaked at $820K in Q3 2021. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

  • Goldman Sachs reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 8,250 Senti Biosciences Holdings shares in Q2 2022, an estimated $814K.
  • Goldman Sachs first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 4 quarters.
  • Goldman Sachs's Senti Biosciences Holdings position peaked at $820K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.